Strategic Forecast for the Bi-Specific MAbS Industry: Market Outlook 2025-2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Bi-Specific MAbS Market Through 2025?
The market size of bi-specific MAbS has experienced a surge in growth in the previous years. The prediction is that it will expand from $7.83 billion in 2024 to $9.1 billion in 2025, with a compound annual growth rate (CAGR) of 16.2%. Factors contributing to the growth during the historical period include heightened spending on healthcare, more funding, and initiatives from government.

What's the Projected Size of the Global Bi-Specific MAbS Market by 2029?
The market size for bi-specific MAbS is anticipated to expand rapidly in the subsequent years. The market is projected to reach $15.19 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 13.7%. The projected growth within this period is due to factors such as a rise in cancer cases, a growing aged population, and a surge in chronic diseases prevalence. Key trends expected within this forecast period include a concentration on technological progress, product innovation, emphasis on artificial intelligence application, investments towards targeted and combination therapies, and the formation of strategic alliances.

View the full report here:
https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

Top Growth Drivers in the Bi-Specific MAbS Industry: What's Accelerating the Market?
The growth of the bispecific monoclonal antibodies market is predicted to be fueled by the escalating occurrence of cancer and other chronic conditions during the forecast timeframe. These antibodies, developed for treating a range of illnesses such as cancer, infectious diseases, disorders of the central nervous system, and autoimmune disorders, are perceived to be more potent than monoclonal antibodies (moAbs) due to their ability to target multiple tumor antigens on cells, thereby inhibiting the progression of cancer. For instance, the American Cancer Society's Cancer Facts & Figures 2023 report predicts 609,820 cancer-related fatalities in the USA in 2023. Hence, the expected rise in chronic diseases, especially cancer, is likely to boost the requirement for bi-specific MAbs as an effective treatment.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

What Trends Will Shape the Bi-Specific MAbS Market Through 2029 and Beyond?
Firms operating within the bi-specific MAbs market are progressively investing in strategic initiatives like collaborations and partnerships. This is intended to enhance their product range and extend their geographic influence. A strategic collaboration is an alliance between two or more firms intended to accomplish shared goals. For example, in October 2022, Gilead Sciences and MacroGenics, both American biopharmaceutical companies, established an exclusive partnership to develop MGD024, a bispecific antibody that targets CD123 and CD3. This was done using MacroGenics' DART platform, along with two other bispecific research programs. This partnership allows Gilead exclusive licensing options for MGD024, which shows promise in treating a range of hematologic cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is designed to decrease the risk of cytokine-release syndrome (CRS) and enables intermittent dosing. This could potentially result in more patient-friendly treatments and better clinical outcomes for those suffering from AML and MDS.

What Are the Main Segments in the Bi-Specific MAbS Market?
The bi-specific MAbS market covered in this report is segmented -

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab
2) By Product Type: In Vivo, In Vitro
3) By Indication: Cancer, Haemophilia A, Ophthalmic
4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:
1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3
2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3
3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)
4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X
5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET
6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A
7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3390&type=smp

Which Top Companies are Driving Growth in the Bi-Specific MAbS Market?
Major companies operating in the bi-specific MAbS market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Parexel, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

Which Regions Will Dominate the Bi-Specific MAbS Market Through 2029?
North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3390

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.